Evidence map›Paper›PMID 27501331›Full record

ArticleCancer science2016

Peperomin E reactivates silenced tumor suppressor genes in lung cancer cells by inhibition of DNA methyltransferase.

Xin-Zhi Wang, Ying Cheng, Kui-Long Wang, Rui Liu, Xiao-Lin Yang, Hong-Mei Wen, Chuan Chai, Jing-Yu Liang, Hao Wu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Anticancer mechanisms of phytochemical compounds: focusing on epigenetic targets.Environmental science and pollution research international · 2021
    Review
  6. Correction.Cancer science · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xin-Zhi WangCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Ying ChengCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Kui-Long WangCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Rui LiuCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Xiao-Lin YangCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Hong-Mei WenCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Chuan ChaiCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jing-Yu LiangDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.
Hao WuCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China. whao5795@vip.sina.com.
Nanjing University of Chinese Medicine · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced lung cancer has poor prognosis owing to its low sensitivity to current chemotherapy agents. Therefore, discovery of new therapeutic agents is urgently needed. In this study, we investigated the antitumor effects of peperomin E, a secolignan isolated from Peperomia dindygulensis, a frequently used Chinese folk medicine for lung cancer treatment. The results indicate that peperomin E has antiproliferative effects, promoting apoptosis and cell cycle arrest in non-small-cell lung cancer (NSCLC) cell lines in a dose-dependent manner, while showing lower toxicity against normal human lung epidermal cells. Peperomin E inhibited tumor growth in A549 xenograft BALB/c nude mice without significant secondary adverse effects, indicating that it may be safely used to treat NSCLC. Furthermore, the mechanisms underlying the anticancer effects of peperomin E have been investigated. Using an in silico target fishing method, we observed that peperomin E directly interacts with the active domain of DNA methyltransferase 1 (DNMT1), potentially affecting its genome methylation activity. Subsequent experiments verified that peperomin E decreased DNMT1 activity and expression, thereby decreasing global methylation and reactivating the epigenetically silenced tumor suppressor genes including RASSF1A, APC, RUNX3, and p16INK4, which in turn activates their mediated pro-apoptotic and cell cycle regulatory signaling pathways in lung cancer cells. The observations herein report for the first time that peperomin E is a potential chemotherapeutic agent for NSCLC. The anticancer effects of peperomin E may be partly attributable to its ability to demethylate and reactivate methylation-silenced tumor suppressor genes through direct inhibition of the activity and expression of DNMT1.

Indexed as

Gene SilencingGenes, Tumor SuppressorAnimalsAntineoplastic AgentsApoptosisBenzodioxolesCell Line, TumorCell SurvivalDisease Models, AnimalDNA (Cytosine-5-)-MethyltransferasesDNA MethylationG1 Phase Cell Cycle CheckpointsHumansLung NeoplasmsMiceModels, MolecularAntineoplastic AgentsBenzodioxolesDNA (Cytosine-5-)-Methyltransferasespeperomin EAnticancer activityDNA (cytosine-5-)-methyltransferase 1non-small-cell lung cancerpeperomin Etumor suppressor genes

Identifiers

PMID27501331
PMCPMC5084666
OpenAlexW2508495626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.